Skip to main content

Dovitinib FDA Approval Status

FDA Approved: No
Generic name: dovitinib
Company: Allarity Therapeutics, Inc.
Treatment for: Renal Cell Carcinoma

Dovitinib is a pan-tyrosine kinase inhibitor in development for the third-line treatment of patients with renal cell carcinoma (RCC).

Development timeline for dovitinib

Dec 22, 2021Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.